HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.

"In light of the Company’s inability to presently predict the duration of the stop ship, the Company believes that it will be ...

Hologic has put forward more data bolstering the use of its artificial intelligence programs for detecting breast cancer through mammography. | Hologic put forward another study that bolsters the use ...

Hologic, a Marlborough-based medical device manufacturer, is expanding its product catalog through the planned $310-million acquisition of Endomagnetics, a breast cancer surgery technology developer.

Between 2016 and 2019, researchers at a top-tier medical facility conducted 7,500 digital breast tomosynthesis (3D ...

Marlborough medical device manufacturer Hologic is anticipating to make an unspecified number of layoffs at international locations this year amid a restructuring of its diagnostics division, as sales ...

In the fourth quarter of fiscal 2025, Diagnostics revenues increased 1.5% in constant currency (CC), driven by higher core ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - imaging, diagnostics ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas, October 21, 2025--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into a definitive agreement to be ...

Hologic stock (NASDAQ: HOLX) has rallied around 83% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $53 after falling to a low of $29 in late March as a rapid increase ...